#AS­CO21: No­var­tis flash­es 'ground­break­ing data' for $2B ra­di­oli­gand drug

Here’s the “ground­break­ing” da­ta from the prostate can­cer drug No­var­tis spent $2 bil­lion to ac­quire: The mol­e­cule hit every end­point in the Phase III tri­al, in­clud­ing ex­tend­ing pa­tient lives by 4 months com­pared to stan­dard of care.

“It’s strik­ing­ly pos­i­tive,” Oliv­er Sar­tor, a prostate can­cer ex­pert at Tu­lane who led the study, told End­points News. “Dur­ing the course of the tri­al, you nev­er re­al­ly know how things are shak­ing out, and I was very, very pleas­ant­ly sur­prised.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN